Devyser Diagnostics (DVYSR) Q4 2025 earnings summary

Executive summary

• Achieved record Q4 2025 sales of SEK 72 million and full-year sales of SEK 250.5 million, with EBIT turning positive at SEK 10.1 million and Q4 EBIT at SEK 18 million (25% margin), reflecting improved profitability from cost control and reorganization.

• Strong cash position of SEK 77.5 million at year-end, with no debt reported.

• Focus remains on profitable growth, cost discipline, innovation, and expansion through partnerships and acquisitions.

Financial highlights

• Q4 revenue reached SEK 72 million, up 12.1% year-over-year; full-year revenue up 15.5% to SEK 250.5 million (20.2% FX adjusted).

• Gross margin for Q4 was 79.5%, with full-year gross margin at 80.6%.

• Q4 EBIT was SEK 18 million (25% margin); full-year EBIT SEK 10.1 million (4% margin).

• Cash flow from operating activities for the year was SEK 8.2 million; Q4 cash flow SEK 12 million.

• Cash and cash equivalents at year-end were SEK 77.5 million.

Outlook and guidance

• Continued cost discipline and current OpEx levels expected to be sustainable in the near term.

• Focus on capitalizing on launched products, R&D for new launches in 2026, and maintaining positive cash flow.

• Growth in the U.S. anticipated to accelerate post-MolDX reimbursement approval, with gradual sales ramp-up from new customers.

• Expansion in Spain with direct sales model and ongoing market share gains in Italy.

• Regulatory progress ongoing, with FDA application for Accept cfDNA study targeted for 2028.